Michael B Jordan Partners With Coach

Coach announces actor and producer Michael B. Jordan as the first worldwide face of the Coach menswear enterprise. His alliance with Coach includes global marketing campaigns for men's ready-to-wear, accessories and fragrance, launching with the Spring 2019 season. The alliance will also include unique design projects with Creative Director Stuart Vevers and charitable efforts with the Coach Foundation.
   
Founded in New York over 75 years ago, Coach began as a man's accessories marque and has built its name on leather invention and artistry. Today, a global fashion brand defined by an unpretentious manner, grounded in New York City. Jordan, a leading man and producer who is delimiting Hollywood standards, is also a long-time friend of the brand. Michael accords the Coach belief in the modern American Dream and values of optimism and inclusiveness.
   
'I'm honored to be joining the Coach family and have so much respect for Stuart Vevers' vision,' said Jordan. 'I'm looking forward to jumping into the creative process and exploring fashion through a different lens.'
   
'Michael is cool and authentic, and he embodies the Coach guy,' said Vevers.  'I've had the chance to get to know Michael over the last couple of years.  He always looks great in Coach, so it felt natural to build our relationship.'


Comments

Post a Comment

Popular posts from this blog

Pepsi Buys Rockstar

Pepsi buys Rockstar .     P epsiCo buys Rockstar Energy Beverages for $3.85 billion.     Founded in 2001, Rockstar is drinks designed for people leading an active lifestyle. Available in 20 flavors at convenience and grocery stores in 30 countries. Distributed by PepsiCo in North America since 2009. Supporting the Rockstar lifestyle across the globe through action sports, motorsports, and live music. Pepsi's energy portfolio also includes Kickstart , GameFuel, and Amp Energy.     The deal reflects the shift from reliance on sales of sugary, fizzy drinks toward options ranging from tea and coffee to still and sparkling water varieties, which appeal to health-conscious and younger consumers. Neither PepsiCo nor Coca-Cola owns a major brand in the energy drinks category, which is forecast to grow to more than $80 billion over the next five years and is now dominated by Red Bull.     2 00 countries and territories around the world enjoy ...
Read more

Compass Buys Marucci

Compass buys Marucci.     Compass Diversified Holdings buys Marucci Sports for $200 million.     Marucci Sports was founded in 2009 by Kurt Ainsworth, a retired pitcher for the San Francisco Giants and Baltimore Orioles, Joe Lawrence, a former second baseman for the Toronto Blue Jays, and Reed Dickens, a former White House Assistant Press Secretary under George W. Bush.     Marucci ’s first buy was Marucci Bat Company, launched out of a backyard shed in 2004. Ainsworth then led the buyout of an Amish-run Pennsylvania wood mill in 2008. This solidified Marucci's superior wood supply, and it still supplies all Marucci's wood today. In 2017 Marucci bought Victus , a baseball equipment maker known for its edgy designs and big attitude.     With vertically cohesive wood bat production, a global supplier group, and a client base of MVPs and World Series winners, Marucci and Victus are the top two bats among Big League players. T...
Read more

Gilead Buys Forty Seven

Gilead buys Forty Seven.     Gilead Sciences buys Forty Seven for $4.9 billion.     Forty Seven is a clinical-stage immuno-oncology firm developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on tech licensed from Stanford. Forty Seven’s lead program, magrolimab , is a monoclonal antibody against the CD47 receptor, a ‘don’t eat me’ signal that cancer cells commandeer to avoid being ingested by macrophages. Evaluated ant ibodies are in many clinical studies of patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. These assets complement the cell therapy franchise Gilead added with its 2017 buy of Kite Pharma .     Beyond magrolimab , Forty Seven is fixing to advance two more compounds into clinical testing. Developing FSI-174, an anti-cKIT antibody, in combination with magrolimab creates a novel, all-antibody conditioning regimen to address ...
Read more